Intermittent Claudication pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook
2020 Intermittent Claudication PIPELINE HIGHLIGHTS
Intermittent Claudication is one of the widely researched conditions during 2020 with 5 companies actively focusing on realizing pipeline’s potential. Development of Intermittent Claudication medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Intermittent Claudication market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Intermittent Claudication.
Good progress is anticipated during 2020 and 2021 with Intermittent Claudication pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Intermittent Claudication pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Intermittent Claudication DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Intermittent Claudication pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Intermittent Claudication pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on Intermittent Claudication presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Intermittent Claudication pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Intermittent Claudication DRUG PROFILES
Intermittent Claudication development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
Both small size and large size pharmaceutical companies are investing their resources in Intermittent Claudication drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Intermittent Claudication. Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 5 Intermittent Claudication companies including company overview, key snapshot, contact information, and their strategies on accelerating Intermittent Claudication pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Companies analyzed in the report include- CardioVascular BioTherapeutics Inc, G. Pohl-Boskamp GmbH & Co KG, ID Pharma Co Ltd, Novartis International AG, Pluristem Therapeutics Inc
REASONS TO BUY
Intermittent Claudication is one of the widely researched conditions during 2020 with 5 companies actively focusing on realizing pipeline’s potential. Development of Intermittent Claudication medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Intermittent Claudication market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Intermittent Claudication.
Good progress is anticipated during 2020 and 2021 with Intermittent Claudication pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Intermittent Claudication pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Intermittent Claudication DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Intermittent Claudication pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Intermittent Claudication pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on Intermittent Claudication presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Intermittent Claudication pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Intermittent Claudication DRUG PROFILES
Intermittent Claudication development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
- Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
- Phase of development
- Mechanism of Action
- Route of Administration
- Companies involved including originator, licensing companies, developer, investors, and others
- New molecular entity details
- Orphan drug designation and other special status provided by regulators
Both small size and large size pharmaceutical companies are investing their resources in Intermittent Claudication drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Intermittent Claudication. Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 5 Intermittent Claudication companies including company overview, key snapshot, contact information, and their strategies on accelerating Intermittent Claudication pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Companies analyzed in the report include- CardioVascular BioTherapeutics Inc, G. Pohl-Boskamp GmbH & Co KG, ID Pharma Co Ltd, Novartis International AG, Pluristem Therapeutics Inc
REASONS TO BUY
- The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
- This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
- Buyers can identify most promising drug candidates for treatment of Intermittent Claudication
- It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
- Users can estimate possible delays in the delivery of pipeline or launch of new products
- Stay ahead of competition through understanding their pipeline progression, strategies and outlook
- The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
- Optimize your licensing and technology transfer strategies through identification of prospect partners
1. INTRODUCTION TO INTERMITTENT CLAUDICATION
1.1 Intermittent Claudication- Disease overview
1.2 Intermittent Claudication- Market Size
1.3 Intermittent Claudication- Companies Involved
2. INTERMITTENT CLAUDICATION PIPELINE SNAPSHOT- 2020
2.1 Intermittent Claudication Pipeline by Phase
2.2 Intermittent Claudication Pipeline by Mechanism of Action
2.3 Intermittent Claudication Pipeline by Route of Administration
2.4 Intermittent Claudication Pipeline- New Molecular Entities
2.5 Intermittent Claudication Pipeline- Orphan Drug Designation/ Special Designation
3. INTERMITTENT CLAUDICATION DRUG PROFILES
3.1 Current Status
3.2 Intermittent Claudication Drug Snapshot
3.3 Intermittent Claudication Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 CardioVascular BioTherapeutics Inc Intermittent Claudication Pipeline Insights and Clinical Trials
4.2 G. Pohl-Boskamp GmbH & Co KG Intermittent Claudication Pipeline Insights and Clinical Trials
4.3 ID Pharma Co Ltd Intermittent Claudication Pipeline Insights and Clinical Trials
4.4 Novartis International AG Intermittent Claudication Pipeline Insights and Clinical Trials
4.5 Pluristem Therapeutics Inc Intermittent Claudication Pipeline Insights and Clinical Trials
5. INTERMITTENT CLAUDICATION MARKET NEWS AND UPDATES
6. APPENDIX
6.1 Sources and Methodology
6.2 Contact Information
1.1 Intermittent Claudication- Disease overview
1.2 Intermittent Claudication- Market Size
1.3 Intermittent Claudication- Companies Involved
2. INTERMITTENT CLAUDICATION PIPELINE SNAPSHOT- 2020
2.1 Intermittent Claudication Pipeline by Phase
2.2 Intermittent Claudication Pipeline by Mechanism of Action
2.3 Intermittent Claudication Pipeline by Route of Administration
2.4 Intermittent Claudication Pipeline- New Molecular Entities
2.5 Intermittent Claudication Pipeline- Orphan Drug Designation/ Special Designation
3. INTERMITTENT CLAUDICATION DRUG PROFILES
3.1 Current Status
3.2 Intermittent Claudication Drug Snapshot
3.3 Intermittent Claudication Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 CardioVascular BioTherapeutics Inc Intermittent Claudication Pipeline Insights and Clinical Trials
4.2 G. Pohl-Boskamp GmbH & Co KG Intermittent Claudication Pipeline Insights and Clinical Trials
4.3 ID Pharma Co Ltd Intermittent Claudication Pipeline Insights and Clinical Trials
4.4 Novartis International AG Intermittent Claudication Pipeline Insights and Clinical Trials
4.5 Pluristem Therapeutics Inc Intermittent Claudication Pipeline Insights and Clinical Trials
5. INTERMITTENT CLAUDICATION MARKET NEWS AND UPDATES
6. APPENDIX
6.1 Sources and Methodology
6.2 Contact Information
